Preparing your Shotlee experience
A recent study has provided real-world evidence of the cardiovascular benefits of tirzepatide, a dual GLP-1 and GIP receptor agonist. The research compared tirzepatide to semaglutide and sitagliptin, finding similar heart protection.
The primary outcome assessed was a combination of major adverse cardiovascular events (MACE), specifically heart attack, stroke, and cardiovascular death. The researchers accounted for various factors that could impact cardiovascular risk, including age, sex, race, pre-existing conditions, and other medications.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from News Directory 3
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨